Loading
A phase 1/2 trial of JK08, Pembrolizumab in metastatic cancer and melanoma, run by Salubris Biotherapeutics Inc, active and no longer recruiting.
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05620134 by Salubris Biotherapeutics Inc, with 263 participants planned, started 2022-10-17 and due to reach its primary completion in 2025-10-17. Interventions recorded: JK08, Pembrolizumab, Lenvatinib Pill. Conditions listed: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/